论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Hu L, Kong F, Pan Y
Received 7 September 2017
Accepted for publication 1 December 2017
Published 5 February 2018 Volume 2018:11 Pages 703—710
DOI https://doi.org/10.2147/OTT.S151129
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Faris Farassati
Purpose: Previous
studies investigating the association between interleukin-17A (IL-17A) G197A
polymorphism and gastric cancer risk have provided inconsistent results. We,
therefore, conducted this meta-analysis to clarify the association between
IL-17A G197A polymorphism and gastric cancer risk.
Methods: We searched PubMed, Excerpta Medica Database, and CNKI databases to
identify relevant studies up to June 10, 2017. A total of 16 case-control
studies including 6,624 cases and 7,631 controls were identified.
Results: Overall, significant associations between IL-17A G197A
polymorphism and gastric cancer risk were observed (A vs G: OR =1.24, 95% CI
=1.14–1.36; AA vs GG: OR =1.63, 95% CI =1.35–1.96; GA vs GG: OR =1.12, 95% CI
=1.01–1.25; AA+GA vs GG: OR =1.23, 95% CI =1.11–1.35; AA vs GA+GG: OR =1.54,
95% CI =1.27–1.87). Similar associations were also observed in Asian population
(A vs G: OR =1.25, 95% CI =1.15–1.37; AA vs GG: OR =1.62, 95% CI =1.33–1.97; GA
vs GG: OR =1.16, 95% CI =1.07–1.25; AA+GA vs GG: OR =1.24, 95% CI =1.15–1.33;
AA vs GA+GG: OR =1.51, 95% CI =1.23–1.85), in Caucasian population (AA vs
GA+GG: OR =2.19, 95% CI =1.40–3.44), and in the hospital-based controls’
subgroup (A vs G: OR =1.30, 95% CI =1.17–1.45; AA vs GG: OR =1.81, 95% CI
=1.46–2.25; AA+GA vs GG: OR =1.27, 95% CI =1.12–1.43; AA vs GA+GG: OR =1.71,
95% CI =1.34–2.18).
Conclusions: The current meta-analysis suggests that IL-17A G197A polymorphism might
enhance gastric cancer risk.
Keywords: gastric cancer, polymorphism, meta-analysis, interleukin-17A,
rs2275913